Related Experiment Video
Updated: Feb 7, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Leveraging the shared and opposing genetic mechanisms in the heritable cardiomyopathies
Daria Kramarenko1,2,3, Poeya Haydarlou1, George Powell4
1Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Insights
Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) have opposing genetic links, yet share some genomic factors. This study identifies 100 loci, aiding in understanding heart muscle diseases and guiding precision medicine.
Area of Science:
- Genetics
- Cardiology
- Genomic Medicine
Background:
- Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are distinct heart muscle diseases with opposing phenotypes.
- Both conditions can lead to severe heart failure and life-threatening arrhythmias.
Purpose of the Study:
- To investigate the largely inverse genetic associations between DCM and HCM.
- To identify genetic loci contributing to the cardiomyopathy spectrum and potential therapeutic targets.
Main Methods:
- Genome-wide association study (GWAS) using data from 9,365 DCM cases, 5,900 HCM cases, and over 1.2 million controls.
- Case-case GWAS approaches to model DCM and HCM as opposing genetic entities.
- Development and validation of polygenic risk scores.
Main Results:
- Identified 100 loci (17 novel) associated with the cardiomyopathy spectrum, with largely inverse associations between DCM and HCM.
- Several identified loci, such as ADM and CACNA2D2, may represent therapeutic targets.
- Polygenic risk scores demonstrated strong discrimination between DCM and HCM patients (AUC 0.78-0.84).
Conclusions:
- The opposing genetic mechanisms of DCM and HCM suggest that therapies may have differential effects.
- A shared genetic locus near CASQ2 and a concordant genomic component related to cardiometabolic health were identified.
- This research defines the genomic architecture of major cardiomyopathy subtypes, paving the way for novel therapeutics and precision medicine in heart failure.
Abstract:
Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are heart muscle diseases with largely opposing structural and functional phenotypes. Yet, both may lead to the same devastating outcomes of advanced heart failure and life-threatening arrhythmias. Using genome-wide association data from 9,365 DCM cases, 5,900 HCM cases, and over 1.2 million controls, we show that DCM and HCM are largely inversely associated across multiple genomic levels. Modeling both disorders as opposing genetic entities, in case-case GWAS approaches, we identify 100 loci (17 novel) underlying the cardiomyopathy spectrum. Several loci map to potential therapeutic targets (e.g., ADM, CACNA2D2), and polygenic risk scores derived from these data show strong discrimination between DCM and HCM patients in external datasets (AUC 0.78-0.84; AUPRC ~ 0.85). The pervasive opposing associations suggest that cardiomyocyte-directed therapies may often have opposite effects in DCM versus HCM. Nevertheless, a shared-effect analysis reveals a single locus - near the calcium-buffering gene CASQ2 - and also identifies a concordant genomic component associated with cardiometabolic health and extracardiac risk factors. By leveraging the shared and opposing genetic mechanisms of DCM and HCM, our work defines the genomic architecture of major cardiomyopathy subtypes and suggests new directions for therapeutics and precision medicine in heart failure.
Related Concept Videos
Heritability
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification

